Placebo-controlled, double-blind, repeated oral dose, clinical pharmacology study of TMG-123 in patients with type 2 diabetes mellitus
Latest Information Update: 15 Sep 2017
At a glance
- Drugs TMG-123 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Teijin Pharma
- 18 Jul 2017 New trial record
- 13 Jun 2017 Results presented at the 77th Annual Scientific Sessions of the American Diabetes Association